213 related articles for article (PubMed ID: 26348890)
1. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
Cowan AJ; Stevenson PA; Cassaday RD; Graf SA; Fromm JR; Wu D; Holmberg LA; Till BG; Chauncey TR; Smith SD; Philip M; Orozco JJ; Shustov AR; Green DJ; Libby EN; Bensinger WI; Shadman M; Maloney DG; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2016 Feb; 22(2):380-385. PubMed ID: 26348890
[TBL] [Abstract][Full Text] [Related]
2. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
Pott C; Schrader C; Gesk S; Harder L; Tiemann M; Raff T; Brüggemann M; Ritgen M; Gahn B; Unterhalt M; Dreyling M; Hiddemann W; Siebert R; Dreger P; Kneba M
Blood; 2006 Mar; 107(6):2271-8. PubMed ID: 16332971
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
Metzner B; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH; Dreyling M; Hoster E; Pott C
Ann Hematol; 2014 May; 93(5):803-10. PubMed ID: 24337447
[TBL] [Abstract][Full Text] [Related]
5. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
[TBL] [Abstract][Full Text] [Related]
6. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
[TBL] [Abstract][Full Text] [Related]
7. Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.
Belotti A; Ribolla R; Cancelli V; Villanacci A; Angelini V; Chiarini M; Giustini V; Facchetti GV; Roccaro AM; Ferrari S; Peli A; Bottelli C; Cattaneo C; Crippa C; Micilotta M; Frittoli B; Grazioli L; Rossi G; Tucci A
Cancer Med; 2021 Sep; 10(17):5859-5865. PubMed ID: 34263564
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
9. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
[TBL] [Abstract][Full Text] [Related]
10. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
[TBL] [Abstract][Full Text] [Related]
11. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.
Noring K; Carlsten M; Sonnevi K; Wahlin BE
BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353
[TBL] [Abstract][Full Text] [Related]
12. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
13. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
Budde LE; Guthrie KA; Till BG; Press OW; Chauncey TR; Pagel JM; Petersdorf SH; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Maloney DG; Gopal AK
J Clin Oncol; 2011 Aug; 29(22):3023-9. PubMed ID: 21730271
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).
García-Noblejas A; Cannata-Ortiz J; Conde E; González Barca E; Gutiérrez N; Rojas R; Vidal MJ; Ramírez MJ; Jiménez-Ubieto A; García-Ruiz JC; Sancho JM; López A; Ríos Rull P; Novelli S; Albo C; Debén G; López-Guillermo A; Nicolás C; González de Villambrosia S; Mercadal S; Martín García-Sancho A; Arranz R
Ann Hematol; 2017 Aug; 96(8):1323-1330. PubMed ID: 28536895
[TBL] [Abstract][Full Text] [Related]
15. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Feyler S; Ross FM; Cook G; Jackson GH; Morgan GJ; Owen RG
J Clin Oncol; 2013 Jul; 31(20):2540-7. PubMed ID: 23733781
[TBL] [Abstract][Full Text] [Related]
17. Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?
Peterlin P; Leux C; Gastinne T; Roland V; Mahé B; Dubruille V; Delaunay J; Chevallier P; Guillaume T; Blin N; Ayari S; Clavert A; Mohty M; Dousset C; Milpied N; Harousseau JL; Moreau P; Wuilleme S; Moreau A; Le Gouill S
Transplantation; 2012 Aug; 94(3):295-301. PubMed ID: 22797728
[TBL] [Abstract][Full Text] [Related]
18. What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?
Kumar A
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):155-162. PubMed ID: 36485104
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Merryman RW; Redd RA; Taranto E; Ahmed G; Jeter E; McHugh KM; Brown JR; Crombie JL; Davids MS; Fisher DC; Freedman AS; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Jacene H; Park H; Dahi PB; Nieto Y; Joyce RM; Chen YB; Shipp MA; Herrera AF; Armand P
Blood Adv; 2023 Sep; 7(17):4748-4759. PubMed ID: 36399518
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
Metzner B; Müller TH; Casper J; Kimmich C; Köhne CH; Petershofen E; Renzelmann A; Thole R; Voss A; Dreyling M; Hoster E; Klapper W; Pott C
Eur J Haematol; 2023 Aug; 111(2):220-228. PubMed ID: 37094812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]